Drug Profile
WT1 TCR-transduced T-cell therapy - Takara Bio
Alternative Names: WT1 antigen-specific RetroNectin TCR gene therapy - Takara Bio; WT1 antigen-specific TCR-gene-transduced autologous lymphocytes - Takara BioLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Takara Bio
- Developer Mie University; Takara Bio
- Class T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Japan (SC)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Second-line therapy or greater) in Japan (SC)
- 03 Dec 2016 Efficacy and safety data from a phase I trial in acute myeloid leukaemia and myelodysplastic syndrome presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)